/Merck%20%26%20Co%20Inc%20billboard-by%20monticello%20via%20Shutterstock.jpg)
With a market cap of $307.3 billion, Merck & Co., Inc. (MRK) develops and markets a broad portfolio of human health pharmaceuticals and vaccines across areas such as oncology, infectious diseases, cardiometabolic disorders, and immunology, alongside a robust animal health business serving livestock and companion animals.
Companies valued at more than $200 billion are generally classified as “mega-cap” stocks, and Merck & Co. fits this criterion perfectly. The company also advances innovation through strategic collaborations and licensing agreements with leading biopharmaceutical partners to develop next-generation therapies worldwide.